As observed in osteoporotic adult patients, bisphosphonate administration after anti-RANKL discontinuation may be required for patients with DMD to inhibit a rebound acceleration of bone turnover and reduce fracture risk, despite the low bone turnover state in GIO. Here, TNFSF11 is linked to Duchenne muscular dystrophy.